Innate Pharma (IPHA) Competitors $1.82 +0.00 (+0.05%) As of 07/3/2025 01:23 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IPHA vs. PHAT, ANAB, IMTX, TRVI, NUVB, DAWN, GHRS, STOK, SANA, and MRVIShould you be buying Innate Pharma stock or one of its competitors? The main competitors of Innate Pharma include Phathom Pharmaceuticals (PHAT), AnaptysBio (ANAB), Immatics (IMTX), Trevi Therapeutics (TRVI), Nuvation Bio (NUVB), Day One Biopharmaceuticals (DAWN), GH Research (GHRS), Stoke Therapeutics (STOK), Sana Biotechnology (SANA), and Maravai LifeSciences (MRVI). These companies are all part of the "pharmaceutical products" industry. Innate Pharma vs. Its Competitors Phathom Pharmaceuticals AnaptysBio Immatics Trevi Therapeutics Nuvation Bio Day One Biopharmaceuticals GH Research Stoke Therapeutics Sana Biotechnology Maravai LifeSciences Phathom Pharmaceuticals (NASDAQ:PHAT) and Innate Pharma (NASDAQ:IPHA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends. Do insiders and institutionals hold more shares of PHAT or IPHA? 99.0% of Phathom Pharmaceuticals shares are held by institutional investors. Comparatively, 0.2% of Innate Pharma shares are held by institutional investors. 23.0% of Phathom Pharmaceuticals shares are held by insiders. Comparatively, 31.9% of Innate Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has higher earnings & valuation, PHAT or IPHA? Innate Pharma has lower revenue, but higher earnings than Phathom Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPhathom Pharmaceuticals$55.25M11.07-$334.33M-$5.24-1.67Innate Pharma$21.77M7.71-$53.53MN/AN/A Which has more volatility & risk, PHAT or IPHA? Phathom Pharmaceuticals has a beta of 0.45, meaning that its stock price is 55% less volatile than the S&P 500. Comparatively, Innate Pharma has a beta of 0.21, meaning that its stock price is 79% less volatile than the S&P 500. Is PHAT or IPHA more profitable? Innate Pharma has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -422.42%. Company Net Margins Return on Equity Return on Assets Phathom Pharmaceuticals-422.42% N/A -90.11% Innate Pharma N/A N/A N/A Do analysts rate PHAT or IPHA? Phathom Pharmaceuticals presently has a consensus target price of $17.50, suggesting a potential upside of 99.66%. Innate Pharma has a consensus target price of $11.00, suggesting a potential upside of 504.06%. Given Innate Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Innate Pharma is more favorable than Phathom Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Phathom Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.00Innate Pharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Does the media favor PHAT or IPHA? In the previous week, Phathom Pharmaceuticals and Phathom Pharmaceuticals both had 1 articles in the media. Phathom Pharmaceuticals' average media sentiment score of 0.00 equaled Innate Pharma'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phathom Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Innate Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryInnate Pharma beats Phathom Pharmaceuticals on 6 of the 11 factors compared between the two stocks. Get Innate Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for IPHA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IPHA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IPHA vs. The Competition Export to ExcelMetricInnate PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$167.76M$2.91B$5.53B$8.95BDividend YieldN/A2.42%5.38%4.08%P/E RatioN/A21.5627.4020.24Price / Sales7.71281.35419.60118.25Price / CashN/A41.9536.6357.47Price / Book16.557.518.085.67Net Income-$53.53M-$55.05M$3.16B$248.47M7 Day Performance-1.57%4.71%2.84%3.32%1 Month Performance-14.91%4.89%3.69%5.20%1 Year Performance-15.30%5.82%35.30%21.35% Innate Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IPHAInnate Pharma2.5713 of 5 stars$1.82+0.1%$11.00+504.1%-15.3%$167.76M$21.77M0.00220PHATPhathom Pharmaceuticals3.6008 of 5 stars$9.59-1.5%$17.50+82.5%-14.5%$679.99M$55.25M-1.83110ANABAnaptysBio2.4516 of 5 stars$22.20-1.2%$42.38+90.9%-3.4%$660.18M$91.28M-4.58100Positive NewsInsider TradeIMTXImmatics2.8905 of 5 stars$5.38-0.9%$14.67+172.6%-52.3%$660.02M$168.65M-31.65260Positive NewsTRVITrevi Therapeutics3.1517 of 5 stars$5.47-2.7%$20.29+270.9%+120.8%$659.19MN/A-12.1620News CoverageAnalyst ForecastAnalyst RevisionNUVBNuvation Bio3.4486 of 5 stars$1.96+1.3%$7.17+266.6%-28.7%$656.71M$7.87M-0.8360High Trading VolumeDAWNDay One Biopharmaceuticals1.732 of 5 stars$6.50+0.5%$30.57+370.3%-49.6%$655.82M$131.16M-9.1560Upcoming EarningsGHRSGH Research1.9356 of 5 stars$12.19-2.0%$32.00+162.5%+23.7%$647.23MN/A-15.4310STOKStoke Therapeutics4.035 of 5 stars$11.35-2.4%$23.20+104.4%-9.4%$634.96M$190.91M14.37100Analyst ForecastSANASana Biotechnology2.629 of 5 stars$2.73-2.8%$8.60+215.0%-38.8%$633.59MN/A-3.10380Analyst ForecastGap UpMRVIMaravai LifeSciences3.6125 of 5 stars$2.41-2.4%$6.64+175.5%-60.4%$629.01M$259.18M-2.11610 Related Companies and Tools Related Companies PHAT Alternatives ANAB Alternatives IMTX Alternatives TRVI Alternatives NUVB Alternatives DAWN Alternatives GHRS Alternatives STOK Alternatives SANA Alternatives MRVI Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IPHA) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innate Pharma S.A. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Innate Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
